A cheaper and potentially shorter pathway to regulatory approval, exclusivity to market, and a bit of free "hey look what we're doing over here at PTX" is a good nudge as well. Let's see how the market reacts, its been slow and thin trading, I've been buying here and there, its probably at the top of my list of accumulation as the pathways to revenues seem a little brighter than many in this space. Watching very closely, this is an exciting company.
Ann: US FDA Grants Orphan Drug Designation to PTX-100 for PTCL, page-4
-
- There are more pages in this discussion • 60 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
